- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: CaCP-29 | IFX-1
Compound class: Antibody
Comment: Vilobelimab (IFX-1) is a chimeric IgG4 monoclonal antibody against the terminal complement component, anaphylatoxin C5a. It was developed for potential to treat complement mediated inflammatory diseases. Vilobelimab blocks C5a/C5aR1 signalling in subsets of myeloid-derived suppressor cells (MDSCs) and neutrophils.
|Targets where the ligand is described in the comment field|
|C5a1 receptor||C5a1 receptor is currently referred to as C5aR1 in the literature. C5a1 has been an attractive target for pharmacological inhibition to treat a myriad of inflammatory and neurodegenerative diseases. Several C5a1 antagonists have been reported that have progressed to various stages of clinical development [4,7,9], although none are yet approved for use in humans. The non-peptide C5aR1 inhibitor CCX168 (Avacopan®), developed by ChemoCentryx, is currently the most clinically advanced C5aR1 inhibitor . The drug has recently completed a Phase III clinical trial for ANCA-associated vasculitis under a concomitant treatment scheme with rituximab or cyclophosphamide/azathioprine (NCT02994927). Considering the potential benefits of blocking the C5a-C5aR1 axis to limit myeloid infiltration and prevent excessive lung inflammation in Coronavirus disease 2019 (COVID-19) , the two anti-C5a/C5aR1 blocking antibodies, avdoralimab (IPH5401) and vilobelimab (IFX-1), are currently being studied in patients with COVID-19 severe pneumonia (NCT04371367 and NCT04333420 for IPH5401 and IFX-1, respectively) .|